Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RADICAVA - Health Canada Drug Approval Details

Approvals/Health Canada/RADICAVA

Authorized

STANDARD

RADICAVA

MITSUBISHI TANABE PHARMA CORPORATION🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 5f9e21f6d336c8eb
Company: MITSUBISHI TANABE PHARMA CORPORATION
Type: Standard

Approval Details

Approval Id: 5f9e21f6d336c8eb
Drug Approval Canada Name: RADICAVA
Product Name: RADICAVA
Status: Marketed
Status Date: 2023-02-09
Original Market Date: 2023-02-09
Din: 02532611
Drug Class: Human
Dosage Form: Suspension
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 28:44.00
Atc Original: N07XX14 EDARAVONE
Atc Name: n 07 xx 14
Aig Number: 0160190002
Company Name: MITSUBISHI TANABE PHARMA CORPORATION
Company Address: 3-2-10 Doshomachi, Chuo-Ku, Osaka-Fu, Japan, 541-0045
Company Detail Path: /organization/mitsubishi-tanabe-pharma-corporation

Company Information

Pharmaceutical Company Name: MITSUBISHI TANABE PHARMA CORPORATION
Country Name: Japan
Province Name: yamagata,country_jp
City Name: yamagata,yamagata,country_jp
Address: 2-2-36, KASUMICHO

Active Ingredients

EDARAVONE

105 MG / 5 ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

5f9e21f6d336c8eb

Type

Standard

Back to Health Canada Approvals